Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,996
  • Shares Outstanding, K 64,507
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,140 K
  • 36-Month Beta 2.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.47
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.32
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/19
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.58 +8.62%
on 02/07/19
0.95 -33.68%
on 01/31/19
-0.05 (-7.35%)
since 01/15/19
3-Month
0.54 +16.45%
on 12/27/18
1.13 -44.25%
on 12/10/18
-0.17 (-21.25%)
since 11/15/18
52-Week
0.54 +16.45%
on 12/27/18
2.21 -71.49%
on 04/04/18
-1.32 (-67.61%)
since 02/15/18

Most Recent Stories

More News
OncoSec To Present At BIO CEO & Investor Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Dan O'Connor, President, Director & Chief Executive Officer, will present...

ONCS : 0.63 (+1.61%)
OncoSec Provides KEYNOTE-695 Clinical Update And Outlines 2019 Milestones

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, provided a clinical data update today regarding KEYNOTE-695, as well as progress of its ongoing...

ONCS : 0.63 (+1.61%)
Safer Treatments Gain Market Traction as Cancer Occurence Continues to Grow

FinancialBuzz.com News Commentary

RNN : 0.57 (-3.39%)
OGEN : 0.95 (+4.40%)
ONCS : 0.63 (+1.61%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0157 (+12.14%)
SNSS : 0.53 (unch)
OncoSec and Gynecologic Oncology Group (GOG) Foundation, Inc. to Conduct a Pivotal Study of TAVO(TM) with Standard of Care KEYTRUDA® for Treatment of Late Stage Cervical Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing novel cancer immunotherapies, today announced it has established a collaboration with the GOG Foundation, Inc., (GOG Foundation),...

ONCS : 0.63 (+1.61%)
OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, announced today that Joon Kim, J.D., a partner at Lee & Ko, has been appointed to OncoSec's...

ONCS : 0.63 (+1.61%)
OncoSec Announces Publication of New Research in the Journal Immunity Highlighting the Role of IL-12 in Anti-PD-1 Therapies with TAVO(TM) Directly Activating TILs in Patients

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing novel cancer immunotherapies, today announced the publication of new research in the journal Immunity that finds that IL-12 producing...

ONCS : 0.63 (+1.61%)
OncoSec Reports Updated Tumor Responses in KEYNOTE-695 Study of TAVO(TM) + KEYTRUDA® in Refractory Metastatic Melanoma

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing novel cancer immunotherapies, today announced an update regarding tumor responses in its KEYNOTE-695 global, multicenter Phase...

ONCS : 0.63 (+1.61%)
OncoSec Presents New Data Showing A Single Cycle Of Monotherapy TAVO(TM) Can Generate Productive Immune Responses In Triple Negative Breast Cancers (TNBC)

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, announced today the presentation of new data that suggests treatment with TAVO(TM) (tavokinogene...

ONCS : 0.63 (+1.61%)
OncoSec Receives $7 Million Investment From Alpha Holdings At $1.50 Per Share

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, announced today that the Company has received a $7.0 million investment at $1.50 per share...

ONCS : 0.63 (+1.61%)
OncoSec Presents New Data During Oral Presentation At Melanoma Bridge Demonstrating Intratumoral Monotherapy TAVO(TM) Induces Abscopal Responses In Metastatic Melanoma Patients

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, announced today the presentation of new data from the company's Phase 2 study of TAVO(TM)...

ONCS : 0.63 (+1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ONCS with:

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

2nd Resistance Point 0.66
1st Resistance Point 0.64
Last Price 0.63
1st Support Level 0.61
2nd Support Level 0.60

See More

52-Week High 2.21
Fibonacci 61.8% 1.57
Fibonacci 50% 1.38
Fibonacci 38.2% 1.18
Last Price 0.63
52-Week Low 0.54

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar